---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-011181"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:32:58.386123+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics reports FY2024 net loss of $57.5M; gene therapy pipeline advances

## Summary
- Net loss of $57.5M ($2.15/sh) vs $10.0M in 2023; revenue $11M from Viatris license.
- Cash $30.3M at year-end; March 2025 financing raised $21.5M, extending runway into H2 2026.
- OPGx-LCA5 Phase 1/2 shows durable response at 12 months; Type D FDA meeting held; pediatric enrollment started.
- OPGx-BEST1 IND-enabling studies done; Phase 1/2 initiation planned for 2025 with preliminary data by Q1 2026.
- Phentolamine LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials fully enrolled; topline data expected mid-2025.

## SEC filing metadata
- accession: 0001140361-25-011181
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/0001140361-25-011181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/ef20046473_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-011181
- JSON: https://secwatch.observer/filing/0001140361-25-011181.json
- Plain text: https://secwatch.observer/filing/0001140361-25-011181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.